Defining clinical improvement in rheumatoid arthritis

Comment

. 1991 Apr;34(4):499-500.

doi: 10.1002/art.1780340420.

Comment

D T Felson et al. Arthritis Rheum. 1991 Apr.

. 1991 Apr;34(4):499-500.

doi: 10.1002/art.1780340420.

No abstract available

Comment on

DAS remission cut points.
Fransen J, van Riel PL. Fransen J, et al. Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-29-32. Clin Exp Rheumatol. 2006. PMID: 17083759 Review.
[Defining remission in Rheumatoid Arthritis. New ACR/EULAR criteria].
Balsa A. Balsa A. Reumatol Clin. 2011 Mar;6S3:S12-5. doi: 10.1016/j.reuma.2010.10.006. Epub 2011 Mar 5. Reumatol Clin. 2011. PMID: 21794765 Spanish.
Defining remission in rheumatoid arthritis: what is it? Does it matter?
Paulus HE. Paulus HE. J Rheumatol. 2004 Jan;31(1):1-4. J Rheumatol. 2004. PMID: 14705208 Review. No abstract available.
Normal serum matrix metalloproteinase-3 levels can be used to predict clinical remission and normal physical function in patients with rheumatoid arthritis.
Hattori Y, Kida D, Kaneko A. Hattori Y, et al. Clin Rheumatol. 2019 Jan;38(1):181-187. doi: 10.1007/s10067-017-3829-9. Epub 2017 Sep 22. Clin Rheumatol. 2019. PMID: 28940139
MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy.
Shiozawa K, Yamane T, Murata M, Yoshihara R, Tsumiyama K, Imura S, Shiozawa S. Shiozawa K, et al. Arthritis Res Ther. 2016 Feb 27;18:55. doi: 10.1186/s13075-016-0948-7. Arthritis Res Ther. 2016. PMID: 26922083 Free PMC article.

Comparing healthcare outcomes.
Orchard C. Orchard C. BMJ. 1994 Jun 4;308(6942):1493-6. doi: 10.1136/bmj.308.6942.1493. BMJ. 1994. PMID: 8019285 Free PMC article.